CN111247137A - 一种嘧啶类化合物、其制备方法及其医药用途 - Google Patents

一种嘧啶类化合物、其制备方法及其医药用途 Download PDF

Info

Publication number
CN111247137A
CN111247137A CN201980005206.4A CN201980005206A CN111247137A CN 111247137 A CN111247137 A CN 111247137A CN 201980005206 A CN201980005206 A CN 201980005206A CN 111247137 A CN111247137 A CN 111247137A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
group
heterocyclyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980005206.4A
Other languages
English (en)
Inventor
司聚同
姜美锋
李加艳
张丽云
樊平平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ancureall Pharmaceutical Shanghai Co Ltd
Original Assignee
Ancureall Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ancureall Pharmaceutical Shanghai Co Ltd filed Critical Ancureall Pharmaceutical Shanghai Co Ltd
Publication of CN111247137A publication Critical patent/CN111247137A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

一种嘧啶类化合物、其制备方法及其医药用途。具体而言，涉及一种通式(I)所示的嘧啶类化合物，及其制备方法，以及其作为细胞周期蛋白依赖性激酶7(CDK7)抑制剂的用途，特别是在预防和/或治疗人类疾病包括癌症中的用途。其中，通式(I)中各基团的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980005206.4A 2018-02-13 2019-01-30 一种嘧啶类化合物、其制备方法及其医药用途 Pending CN111247137A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101500510 2018-02-13
CN201810150051 2018-02-13
PCT/CN2019/073874 WO2019157959A1 (zh) 2018-02-13 2019-01-30 一种嘧啶类化合物、其制备方法及其医药用途

Publications (1)

Publication Number Publication Date
CN111247137A true CN111247137A (zh) 2020-06-05

Family

ID=67619169

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980005206.4A Pending CN111247137A (zh) 2018-02-13 2019-01-30 一种嘧啶类化合物、其制备方法及其医药用途

Country Status (3)

Country Link
CN (1) CN111247137A (zh)
TW (1) TW201934547A (zh)
WO (1) WO2019157959A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114133394A (zh) * 2020-08-12 2022-03-04 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227125A1 (zh) * 2022-05-26 2023-11-30 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014063068A1 (en) * 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015154039A2 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014063068A1 (en) * 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015154039A2 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106458990A (zh) * 2014-04-04 2017-02-22 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NICHOLAS KWIATKOWSKI等: "Targeting transcription regulation in cancer with a", 《NATURE》 *
WANG,YUBAO等: "CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer", 《CELL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114133394A (zh) * 2020-08-12 2022-03-04 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途

Also Published As

Publication number Publication date
WO2019157959A1 (zh) 2019-08-22
TW201934547A (zh) 2019-09-01

Similar Documents

Publication Publication Date Title
JP7073316B2 (ja) 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
JP6869947B2 (ja) 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
JP6947651B2 (ja) ４，６−ピリミジニレン誘導体およびこれらの使用
JP6333277B2 (ja) 化合物およびその使用方法
US20100210646A1 (en) 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
JP6866967B2 (ja) サイクリン依存性キナーゼｃｄｋ９の新規阻害剤
TW200808771A (en) Novel compounds II
CN112585119A (zh) 经取代的吲哚及其使用方法
WO2012041524A1 (en) Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
EP3078660B1 (en) Novel quinazoline derivative
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
CN111566100A (zh) 嘧啶类化合物、其制备方法及其医药用途
BR112021014977A2 (pt) Derivados de acetamido como inibidores de dna polimerase teta
PT1636215E (pt) Furazanobenzimidazoles
WO2017143874A1 (zh) 一种取代的恶二唑类化合物及包含该化合物的组合物及其用途
CN111247137A (zh) 一种嘧啶类化合物、其制备方法及其医药用途
CN110691775B (zh) 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
WO2022095904A1 (zh) 吡唑并哒嗪酮化合物、其药物组合物及其用途
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
WO2020082817A1 (zh) 肟基萘醌类化合物及其制备方法和用途
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
CN114341128A (zh) 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
CN112341434B (zh) PI3K/mTOR蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
CN104177312B (zh) 一种含硒化合物及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019956

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200605